Cell News and Research

RSS

Enrollment complete in Ceregene's CERE-120 Phase 2b trial for Parkinson's

Ceregene, Inc. reported today that it has completed enrollment in its Phase 2b trial of CERE-120, a gene therapy product expressing the neurturin (NRTN) gene for the treatment of Parkinson's disease.

1 Dec 2011

Corning completes acquisition of Mediatech

Corning Incorporated announced today that it has completed the acquisition of Mediatech, Inc., a Virginia-based corporation, including Mediatech's subsidiary, KD Medical, Inc., a Maryland-based corporation.

1 Dec 2011

Celldex launches rindopepimut Phase 3 trial in EGFRvIII-positive glioblastoma

Celldex Therapeutics, Inc. today announced that it has launched a pivotal, randomized, double-blind, controlled Phase 3 trial of rindopepimut in patients with surgically resected epidermal growth factor variant III (EGFRvIII)-positive glioblastoma, the "ACT IV Study."

1 Dec 2011

New discovery of adult stem cells gives fresh possibilities for heart regeneration

Sydney researchers have discovered a new population of adult stem cells in the heart, which could augment the development of new regeneration and repair therapies for people who have suffered heart attack or heart failure, the leading cause of death in Australia.

1 Dec 2011

Study presents high-resolution genome-wide p53-binding map for normal human cells

Scientists investigating the interactions, or binding patterns, of a major tumor-suppressor protein known as p53 with the entire genome in normal human cells have turned up key differences from those observed in cancer cells. The distinct binding patterns reflect differences in the chromatin (the way DNA is packed with proteins), which may be important for understanding the function of the tumor suppressor protein in cancer cells.

1 Dec 2011

Botulism toxins could be re-engineered for treating RA, asthma, psoriasis

The most poisonous substance on Earth - already used medically in small doses to treat certain nerve disorders and facial wrinkles - could be re-engineered for an expanded role in helping millions of people with rheumatoid arthritis, asthma, psoriasis and other diseases, scientists are reporting. Their study appears in ACS' journal Biochemistry.

1 Dec 2011

Compugen's Antibody Target Discovery Platform presented at 7th Annual European Antibody Congress

Speaking today at the plenary session of the 7th Annual European Antibody Congress in Geneva, Dr. Anat Cohen-Dayag, President and CEO of Compugen Ltd., presented Compugen's Antibody Target Discovery Platform, one of the Company's predictive discovery platforms for novel therapeutic targets.

1 Dec 2011

Immune system stimulant used as suppressor to treat chronic graft-versus-host disease

In a study that seems to pivot on a paradox, scientists at Dana-Farber Cancer Institute have used an immune system stimulant as an immune system suppressor to treat a common, often debilitating side effect of donor stem cell transplantation in cancer patients. The effect, in some cases, was profound.

1 Dec 2011

Combination of two techniques promises to improve effectiveness of experimental gene therapies

yeast or phages act not only to tag and target but also to exchange specific genes in DNA A combination of two techniques promises to improve the efficiency and effectiveness of experimental gene therapies, while also reducing potential side effects says a new research report published in the December 2011 issue of the FASEB Journal.

1 Dec 2011

Onconova uses BioClinica EDC, data management services to support clinical trials

BioClinica, Inc., a global provider of clinical trial management solutions, today announced that Onconova Therapeutics, Inc. has extended agreements using BioClinica Express electronic data capture (EDC) and data management services to support their clinical trials world-wide.

From Clario 1 Dec 2011

arGEN-X closes EUR 27.5 million Series B fundraising round

arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody platform, announced today the closing of a EUR 27.5 million (USD 37 million) Series B fundraising round, which was oversubscribed.

1 Dec 2011

Novel nanocarbon platform shows potential for future bioelectronic implants

Researchers have demonstrated, for the first time, a graphene-based transistor array that is compatible with living biological cells and capable of recording the electrical signals they generate.

1 Dec 2011

Idera regains global rights to IMO-2055 from Merck KGaA for treatment of cancer

Idera Pharmaceuticals, Inc. today announced that it has regained global rights to IMO-2055, an agonist of Toll-like Receptor (TLR) 9, as part of an agreed-upon termination of its oncology collaboration with Merck KGaA, Darmstadt, Germany.

1 Dec 2011

Researchers identify first gene associated with frequent herpes-related cold sores

A team of researchers from the University of Utah and the University of Massachusetts has identified the first gene associated with frequent herpes-related cold sores.

1 Dec 2011

Oral ingestion of apple polyphenols can prevent colitis in mice

Here's another reason why "an apple a day keeps the doctor away"-according to new research findings published in the Journal of Leukocyte Biology, oral ingestion of apple polyphenols can suppress T cell activation to prevent colitis in mice.

1 Dec 2011

Researchers reveal stress-induced machinery of protein synthesis involved in bacterial cell death

Researchers at the Hebrew University of Jerusalem and the University of Vienna have revealed for the first time a stress-induced machinery of protein synthesis that is involved in bringing about cell death in bacteria.

1 Dec 2011

Joslin study uncovers potential targets for soft-tissue sarcomas

Scientists at Joslin Diabetes Center in Boston have uncovered important molecular and genetic keys to the development of soft-tissue sarcomas in skeletal muscle, giving researchers and clinicians additional targets to stop the growth of these often deadly tumors.

30 Nov 2011

Combination treatment improves progression-free survival in pancreatic neuroendocrine tumors

Combination treatment with everolimus, an inhibitor of the mammalian target rapamycin (mTOR), and octreotide has shown to improve progression-free survival for patients with advanced neuroendocrine tumors and a history of carcinoid syndrome, according to researchers at The University of Texas MD Anderson Cancer Center.

30 Nov 2011

ACGME approves Cedars-Sinai's neurology residency training program

The Accreditation Council for Graduate Medical Education has approved a neurology residency training program at Cedars-Sinai Medical Center. Recruitment of the first group of three residents is under way through the 2012 "match," a process in which an independent organization pairs applicants with programs to meet the preferences of each.

30 Nov 2011

Affymetrix signs definitive agreement to acquire eBioscience

Affymetrix, Inc., today announced that it has signed a definitive agreement to acquire eBioscience, Inc., a privately-held San Diego, CA-based company with an industry-leading position in flow cytometry and immunoassay reagents for immunology and oncology research and diagnostics. Under the terms of the agreement, Affymetrix will acquire eBioscience for $330 million in cash subject to certain customary adjustments.

30 Nov 2011

Cell News and Research

Enrollment complete in Ceregene's CERE-120 Phase 2b trial for Parkinson's

Corning completes acquisition of Mediatech

Celldex launches rindopepimut Phase 3 trial in EGFRvIII-positive glioblastoma

New discovery of adult stem cells gives fresh possibilities for heart regeneration

Study presents high-resolution genome-wide p53-binding map for normal human cells

Botulism toxins could be re-engineered for treating RA, asthma, psoriasis

Compugen's Antibody Target Discovery Platform presented at 7th Annual European Antibody Congress

Immune system stimulant used as suppressor to treat chronic graft-versus-host disease

Combination of two techniques promises to improve effectiveness of experimental gene therapies

Onconova uses BioClinica EDC, data management services to support clinical trials

arGEN-X closes EUR 27.5 million Series B fundraising round

Novel nanocarbon platform shows potential for future bioelectronic implants

Idera regains global rights to IMO-2055 from Merck KGaA for treatment of cancer

Researchers identify first gene associated with frequent herpes-related cold sores

Oral ingestion of apple polyphenols can prevent colitis in mice

Researchers reveal stress-induced machinery of protein synthesis involved in bacterial cell death

Joslin study uncovers potential targets for soft-tissue sarcomas

Combination treatment improves progression-free survival in pancreatic neuroendocrine tumors

ACGME approves Cedars-Sinai's neurology residency training program

Affymetrix signs definitive agreement to acquire eBioscience

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest Life Science News